PharVision Advisers’s Intel INTC Stock Holding History

PharVision Advisers’s Portfolio INTC Stock Details INTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,355	Closed	-$271K	–	368
2025 Q4	$271K	Buy	+7,355	New	+$278K	0.14%	338

Other funds holding INTC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nvidia Corp Santa Clara, California $18.4B AUM 362.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PharVision Advisers's INTC Position: Q1 2026 in Review

PharVision Advisers sold out of Intel (INTC) in Q1 2026, closing a stake of 7,355 shares — an estimated $271K sold.

PharVision Advisers first reported a position in INTC in Q4 2025 and held it in 1 quarter. The position peaked at $271K in Q4 2025. 2,568 funds tracked by Wall St. Rank hold INTC as of Q1 2026.

PharVision Advisers reported no remaining Intel position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 7,355 Intel shares in Q1 2026, an estimated $271K.
PharVision Advisers first reported a position in Intel in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Intel position peaked at $271K in Q4 2025.
2,568 funds tracked by Wall St. Rank held Intel as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.